{
    "organizations": [],
    "uuid": "00a8ad16eb340465f787992a97947754ffe5174d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/regeneron-pharms-results/regenerons-first-quarter-profit-soars-92-percent-idUSL3N1SA3QV",
    "ord_in_thread": 0,
    "title": "Regeneron's first quarter profit soars 92 percent",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.\nNet income rose to $478 million, or $4.16 per share, in the quarter ended March. 31, from $248.9 million, or $2.16 per share, a year ago.\nTotal revenue rose to $1.51 billion from $1.32 billion. (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)\nOur ",
    "published": "2018-05-03T18:35:00.000+03:00",
    "crawled": "2018-05-04T17:04:28.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "thursday",
        "posted",
        "percent",
        "rise",
        "quarterly",
        "profit",
        "demand",
        "flagship",
        "eye",
        "treatment",
        "eylea",
        "eczema",
        "drug",
        "dupixent",
        "increased",
        "net",
        "income",
        "rose",
        "million",
        "per",
        "share",
        "quarter",
        "ended",
        "march",
        "million",
        "per",
        "share",
        "year",
        "ago",
        "total",
        "revenue",
        "rose",
        "billion",
        "billion",
        "reporting",
        "tamara",
        "mathias",
        "bengaluru",
        "editing",
        "shailesh",
        "kuber"
    ]
}